NovaBridge Biosciences
Nasdaq · Healthcare · Pharmaceutical Preparations · Rockville, MD
NBP chart
What traders are saying about $NBP
Latest postsNovaBridge Biosciences news
- [ESMO] NovaBridge Biosciences CEO Gupta: “Givastomig to pursue technology transfer and in-house Phase 3 clinical trials”
더바이오 ·
- NovaBridge Biosciences (NBP) stock price, news, quote and history
Yahoo Finance UK ·
- NovaBridge Biosciences Reports Mature Phase 1b Data at ESMO 2026 Positioning Givastomig for Registrational Development
Yahoo Finance ·
- NovaBridge Biosciences Estimates – NASDAQ:NBP
TradingView ·
- Drug dosing is the focus of NovaBridge Biosciences (NBP) and ABL Bio's early trial update.
Stock Titan ·
- Visara Secures Exclusive Option for Potential Acquisition of YOL104-2 for Ocular Surface Squamous Neoplasia
Yahoo Finance ·
- Visara Expands Ophthalmology Pipeline with Exclusive License for Investigational Nerve Growth Factor Therapy for Neurotrophic Keratitis
Yahoo Finance ·
- NovaBridge Biosciences Announces Expanded Givastomig Safety and Efficacy Data to be Presented at the European Society for Medical Oncology 2026
Yahoo Finance ·
- NovaBridge Appoints Martin Dewhurst to Board of Directors as an Independent Director
Yahoo Finance ·
- NovaBridge Biosciences to Participate in September Investor Conferences
Yahoo Finance ·
- NovaBridge Biosciences (NBP) (H1 2026) Earnings Call Highlights: Strong Cash Position and ...
Yahoo Finance ·
- NovaBridge Biosciences Q2 2026 Earnings Call Summary
app.moby.co ·
NovaBridge Biosciences key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | – | – | $632,000 | -$1.6M |
| Net income | -$46.3M | -$22.2M | -$207.7M | -$371.1M |
| Diluted EPS | $-0.21 | $-0.12 | $-1.09 | $-1.96 |
| Total assets (year end) | $260.5M | $212.7M | $368.9M | $590.6M |
| Cash and equivalents (year end) | $210.6M | $68.3M | $291.5M | $342.9M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About NovaBridge Biosciences
- Ticker
- NBP (Nasdaq)
- Industry
- Pharmaceutical Preparations
- Headquarters
- Rockville, MD
- Incorporated in
- Cayman Islands
- Fiscal year end
- December 31
- SEC CIK
- 1778016
- Former names
- I-Mab
Frequently asked questions
What exchange is NovaBridge Biosciences listed on?
NovaBridge Biosciences trades on the Nasdaq under the ticker symbol NBP.
What industry is NovaBridge Biosciences in?
NovaBridge Biosciences is classified by the SEC under "Pharmaceutical Preparations", part of the Healthcare sector on StockTweeting.
Where is NovaBridge Biosciences headquartered?
NovaBridge Biosciences's business address on file with the SEC is in Rockville, MD.
When does NovaBridge Biosciences's fiscal year end?
NovaBridge Biosciences's fiscal year ends on December 31.
How much revenue did NovaBridge Biosciences report?
NovaBridge Biosciences reported $632,000 in revenue for calendar year 2023, according to its SEC filings.